SCHEDULE: Intracoastal Capital Discloses 9.99% Stake in Silo Pharma
Beneficial Ownership Report
Intracoastal Capital LLC and its principals, Mitchell P. Kopin and Daniel B. Asher, reported a 9.99% beneficial ownership stake in Silo Pharma, Inc. as of December 31, 2025.
Summary
- Reporting Persons: Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
- Beneficial Ownership: 1,478,164 shares of Silo Pharma, Inc. common stock.
- Percentage of Class: 9.99% of the outstanding common stock.
- Basis of Ownership: This includes 833,334 shares issuable from Intracoastal Warrant 1 and 644,830 shares from Intracoastal Warrant 2.
- Shares Outstanding: Based on 13,318,273 shares outstanding as of October 27, 2025, as reported by Silo Pharma, Inc.
- Blocker Provisions: The reporting persons hold additional warrants (Intracoastal Warrants 2, 3, 4, and 5) with blocker provisions that prevent beneficial ownership from exceeding 9.99% or 4.99%, depending on the warrant. Without these provisions, their beneficial ownership would be 3,344,905 shares.
- Purpose: The securities were not acquired or held for the purpose of changing or influencing control of the issuer.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral. It is a routine disclosure of a significant passive ownership stake, which provides transparency but does not inherently convey positive or negative sentiment about the issuer's performance or prospects.
Future Outlook
NA
Industry Context
StockSavvy.ai notes that a 9.99% passive stake by an investment entity like Intracoastal Capital LLC is a significant position, often indicating a long-term investment perspective in the biotechnology or pharmaceutical sector, where Silo Pharma operates. Such disclosures are common for institutional investors accumulating positions in emerging growth companies.
Comparison to Industry Standards
- StockSavvy.ai observes that a 9.99% stake is just below the 10% threshold that would typically trigger additional reporting requirements and potentially classify the investor as an insider. This level of ownership is a common strategy for institutional investors to maintain a significant, yet passive, influence without incurring the full regulatory burden of an active control position.
- For example, similar passive stakes are often seen in early-stage biotech companies where institutional investors like Perceptive Advisors or RA Capital Management build positions, often through warrants, to support growth while maintaining flexibility.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence or interest in the company.
- Company Management: Awareness of a large passive shareholder, which could influence strategic decisions or future capital discussions.
Key Dates
| Date | Description |
|---|---|
| 2025-10-27 | Date Silo Pharma, Inc. reported 13,318,273 shares of Common Stock outstanding. |
| 2025-12-31 | Date of event requiring the filing of this statement, reflecting the beneficial ownership position. |
| 2026-02-13 | Date the Schedule 13G was signed by Mitchell P. Kopin and Daniel B. Asher. |
Keywords
Silo Pharma, Intracoastal Capital, Mitchell P. Kopin, Daniel B. Asher, Schedule 13G, beneficial ownership, common stock, warrants, equity stake, SEC filing
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.